Skip to main content
. 2023 Oct 27;30(10):2233–2244. doi: 10.1158/1078-0432.CCR-22-3573

Figure 5.

Figure 5. Genomic alterations in the abemaciclib and placebo groups in MONARCH 3 and the abemaciclib monotherapy group in nextMONARCH (TR2 population). A, Acquired genomic alterations. *, P < 0.05 abemaciclib versus placebo in MONARCH 3. B, The frequency of individual ESR1 mutations (found in ≥2 patients) acquired during treatment. C, Genomic alterations detected at baseline but not detected at EOT. TR2 population consists of patients with a valid ctDNA sample at both baseline and EOT. NSAI, nonsteroidal aromatase inhibitor.

Genomic alterations in the abemaciclib and placebo groups in MONARCH 3 and the abemaciclib monotherapy group in nextMONARCH (TR2 population). A, Acquired genomic alterations. *, P < 0.05 abemaciclib versus placebo in MONARCH 3. B, The frequency of individual ESR1 mutations (found in ≥2 patients) acquired during treatment. C, Genomic alterations detected at baseline but not detected at EOT. TR2 population consists of patients with a valid ctDNA sample at both baseline and EOT. NSAI, nonsteroidal aromatase inhibitor.